Emerging drugs for the treatment of chronic pruritic diseases

Kayla Fourzali, Rachel Shireen Golpanian, Gil Yosipovitch

Research output: Contribution to journalReview article

Abstract

Introduction: Chronic pruritus is non-histaminergic and mediated through a complex interplay of peripheral and central immune and neural pathways. Significant developments in the understanding of chronic pruritus have emerged and paved the way for new, emerging therapies. Areas covered: This review details the emerging drug landscape for chronic pruritus treatment, focusing on monoclonal antibody agents that target key cytokines and their receptors as well as small molecule agents that inhibit mediators of the immune and neural pathways. The article provides background regarding the currently available therapies and the rationale for the development of new agents based on the current market and recent scientific developments. Expert opinion: Identification of new targets along neuroimmune itch pathways has allowed for the development of targeted drugs which can be utilized for effective therapy. As we enter a new era of chronic itch treatments, we face exciting prospects and challenges.

Original languageEnglish (US)
JournalExpert Opinion on Emerging Drugs
DOIs
StateAccepted/In press - 2020

Keywords

  • biologics
  • chronic itch
  • clinical trials
  • JAK inhibitors
  • monoclonal antibodies
  • Pruritus
  • small molecule agents

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Emerging drugs for the treatment of chronic pruritic diseases'. Together they form a unique fingerprint.

  • Cite this